.svg)
As we turn the page to 2025, I’m filled with gratitude and excitement for the journey ahead. Reflecting on the past year, 2024 stands out as a truly transformational period for our company, marked by pivotal achievements that set the stage for a paradigm shift in molecular diagnostics where test results are fast and actionable, and the actions taken can significantly improve things such as yields, timelines, costs and loss reduction, health outcomes, etc.
First and foremost, our agreement with the Centers for Disease Control and Prevention (CDC) represents a cornerstone of our mission. Collaborating with the CDC to develop a molecular test for Avian Influenza (H5N1) in humans at the point of care underscores our commitment to addressing global health challenges with speed and precision.
In agriculture, we achieved another milestone with the launch of our Alveo Sense Poultry Avian Influenza test in Europe and the Middle East in partnership with GD Animal Health. This innovative solution will empower veterinarians and poultry integrators to detect and address outbreaks with accuracy and efficiency, bolstering both animal health and food security.
We also welcomed Chris Cowen, an exceptional leader to our team, as our Chief Commercial Officer. Chris brings deep expertise and a vision for growth that will help us scale our impact across industries and geographies.
Finally, the launch of the academic arm of our partner program and our RUO developer kit has paved the way for groundbreaking research collaborations. This program is fostering innovation and creating opportunities for research and academic institutions to explore new and/or improved applications of our technology.
I believe the highlights of 2024 represent more than progress for Alveo, they are truly a jumping-off point for what’s to come in 2025. This year, we aim to drive significant revenue/volume growth of recently launched products, deepen our existing partnerships and for new partnerships, expand the reach of our products, and continue driving the much-needed paradigm shift in molecular testing.
In my experience, it takes the right culture and the right teams and individuals to build something special. The Alveo team and our existing world-class partners are doing just that. Together, we are shaping a future where accurate, actionable diagnostics are accessible to all. Here’s to an extraordinary year ahead!
